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Abstract
Background: In HIV-infected individuals, mechanisms underlying unsatisfactory immune recovery during effective
combination antiretroviral therapy (cART) have yet to be fully understood. We investigated whether polymorphism of genes
encoding immune-regulating molecules, such as killer immunoglobulin-like receptors (KIR) and their ligands class I human
leukocyte antigen (HLA), could influence immunological response to cART.
Methods: KIR and HLA frequencies were analyzed in 154 HIV-infected and cART-treated patients with undetectable viral
load divided into two groups: ‘immunological non responders’ (INR, N=50, CD4
+ T-cell count ,200/mm
3) and full
responders (FR, N=104, CD4
+ T-cell count .350/mm
3). Molecular KIR were typed using polymerase chain reaction-based
genotyping. Comparisons were adjusted for baseline patient characteristics.
Results: The frequency of KIR2DL3 allele was significantly higher in FR than in INR (83.7% vs. 62%, P=0.005). The functional
compound genotype HLA-C1
+/KIR2DL3
+, even at multivariable analysis, when adjusted for nadir CD4
+ T-cell count, was
associated with reduced risk of INR status: odds ratio (95% Confidence Intervals) 0.34 (0.1320.88), P=0.03.
Conclusions: Reduced presence of the inhibitory KIR2DL3 genotype detected in INR might provoke an imbalance in NK
function, possibly leading to increased immune activation, impaired killing of latently infected cells, and higher proviral
burden. These factors would hinder full immune recovery during therapy.
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Introduction
Combination antiretroviral therapy (cART) has dramatically
reduced morbidity and mortality in individuals infected with
human immunodeficiency virus (HIV) [1]. Nevertheless, up to
30% of HIV-infected patients, despite virologically effective cART
with undetectable plasma viral load, fail to achieve a satisfactory
immunological recovery [2], defined as a CD4
+ T-cell count
$200/mm
3. Despite been intensive investigation regarding the
subject, possible mechanisms explaining this phenomenon remain
largely unexplained. Low nadir CD4
+ T-cell count, hepatitis C or
other viral coinfection, age, previous AIDS-defining events, history
of cART and duration of suppressive cART have all been
associated with an impaired immune reconstitution [3]. More
recently, higher immune activation and T-cell turnover, and
higher proviral burden were found to be linked to reduced
immune recovery [4]. As yet undefined host factors might explain
the diversity between patients of immunological responses to
cART: a role of genetic polymorphisms of cytokines [5] and
human leukocyte antigen (HLA) molecules [6] has been suggested.
The impact of host genetic variation on outcome of HIV
infection in the absence of antiretroviral therapy has been well
documented, with recent focus on genes encoding for HLA class I
molecules, whose polymorphism influences HIV control [7,8].
The crucial role of host genetics in determining interindividual
levels of protections against HIV has been further highlighted by
the discovery of HLA class I as ligands for killer cell
immunoglobulin-like receptors (KIR), a polymorphic set of
molecules that modulate natural killer (NK) cell activity [9].
Specific epistatic interactions between HLA- and KIR-encoding
genes were found to be associated with a delay in disease
progression and a stronger viral control in HIV-infected cART
naı ¨ve individuals [10,11]: the functional interaction between
HLA-B Bw4-Ile4 and KIR3DS1, it has been suggested, leads to
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1-infected cells [12]. Modulation of receptor expression on NK
cells may also play a role in the pathogenesis of HIV-1 disease
progression, as recently shown by the discovery of reduced
KIR2DS1 and KIR2DL1 presence on NK surfaces in advanced
HIV-1 disease [13].
Prompted by these findings, we investigated whether distinct
KIR-HLA genetic profiles may play a role in failed immune
recovery of HIV-infected individuals treated with virologically
effective cART.
Methods
Ethic statement and subjects
A group of 154 unrelated HIV-infected individuals were
enrolled in the Infectious Diseases Unit of San Gerardo Hospital
in Monza, Luigi Sacco Hospital in Milan, and San Matteo
Hospital in Pavia, all the three in the Lombardy region of northern
Italy. The study was approved by the review board of the three
institutions (San Gerardo Hospital, Monza, Italy, Luigi Sacco
Hospital, Milano, Italy, and San Matteo Hospital, Pavia, Italy).
Patients participating in this study gave written informed consent
according to the Declaration of Helsinki.
Inclusion criteria were stable cART for .12 months, HIV RNA
,50 copies/mL over the last 6 months and written informed
consent to participate to the study. On the basis of CD4
+ responses
to stable and suppressive cART, patients were divided into two
groups: immunological non responders (INR), CD4
+ #200/mm
3,
and full responders (FR), CD4
+ $350/mm
3. One-hundred-and-
three HIV-negative subjects were evaluated as healthy controls
(HC) in order to account for possible bias in the selection of HIV-
infected population.
Demographic and laboratory parameters were retrieved from
patients’ files. Stored samples were used to perform KIR and HLA
genotyping.
HLA and KIR Genotyping
Genomic DNA was isolated from peripheral blood using
standard procedures. Molecular typing of HLA B, Cw, and KIR
was performed by PCR using sequence specific primers (SSP)
method with commercial kits, according to the manufacturer’s
instructions (BAG- Lich, Germany; Invitrogen Corporation,
Carlsbad, CA, USA). Detection of the alleles recognized by the
specific primers was done after amplification in a GeneAmp PCR
9700 thermocycler (Applied Biosystem, Foster City, CA, USA) by
gel electrophoresis on 2% agarose gel.
KIR haplotype and ligands
Genotypes can be resolved into two broad haplotypes, termed A
and B, based on KIR gene content.
The B haplotype is defined by the presence of one or more of
the following genes: 2DL2, 2DL5, 3DS1, 2DS1, 2DS2, 2DS3, 2DS5.
If none of these are present, an AA genotype is defined.
In the A haplotype it is exceptionally rare to find variability in
gene content, but there is much more allele variability. In order to
classify A and/or B haplotypes we referred to the criteria adopted
by Middleton on the interactive website of allele frequencies
(http://www.allelefrequencies.net), which did not distinguish
between AB and BB genotypes, and called any of these Bx [14,15].
Ligands group were defined as follows:
i. KIRs 2DL1 and 2DS1 have as their ligand the C2 epitope
(Asparagine at position 77, Lysine at position 80) present in
most of HLA-Cw2, -Cw4, -Cw5, -Cw6, -Cw15, -Cw17, -Cw18
alleles.
ii. KIRs 2DL2, 2DL3 and 2DS2 have as their ligand the C1
epitope (Serine at position 77, Asparagine at position 80)
present in most of HLA-Cw1, -Cw3, -Cw7, -Cw8, -Cw12,
-Cw14, -Cw16 alleles [16].
iii. In addition, HLA-G was considered ligand for 2DL4, HLA-
Bw4 motif for 3DL1 (and 3DS1), HLA-A3 A11 for 3DL2,
and HLA-Cw4 for 2DS4, as already reported; ligands for the
other receptors are still unknown [14,15].
Statistical analysis
Differences between groups were assessed by the chi-square test
for categorical variables. Fisher exact test was performed when
appropriated; Student’s t test and Mann Withney test were
adopted for continuous variables, as appropriate. All statistical
tests were two-sided and differences were considered statistically
significant at P,0.05. Since the present study was largely
exploratory, corrected P values were not reported. The association
of each polymorphism with the immunological outcome (FR or
INR status) was measured by the Odd Ratio (OR) and its 95%
Confidence of Interval (95%CI). For each independent variable,
crude and adjusted ORs and 95% CIs were calculated. In the
unconditional multiple logistic regression model, including all
variables associated in the crude analysis, nonsignificant variables
were eliminated in a stepwise, backward elimination algorithm, to
Table 1. Demographic and viro-immunological
characteristics of 154 HIV-1-infected patients, according to
immunological response to combination antiretroviral
therapy.
INR FR P-value
N=50 N=104
Age, y. 49.9 (11.4) 46.9 (9.1) NS
Female gender, no. (%) 12 (24.0) 29 (27.9) NS
Mode of transmission, No. (%) NS
- IVDU 15 (30.0) 30 (28.9)
- HETERO 27 (54.0) 55 (52.9)
- MSM 8 (16.0) 17 (16.3)
- OTHER/UNKNOWN 0 (0.0) 2 (1.9)
CDC Stage, No. (%) 0.027
- A 11 (22.0) 44 (43.1)
- B 12 (24.0) 25 (24.5)
- C 27 (54.0) 33 (32.4)
UNKNOWN 0 (0.0) 2 (1.9)
Years of HIV infection 14.3 (9.4) 17.2 (6.7) NS
Duration of cART, y. 11 (15) 16 (11) 0.045
Nadir CD4
+ T-cell count, cells/mm
3 62 (56) 169 (114) ,0.0001
HBV co-infection, No. (%) 3 (6.0) 7 (8.1) NS
HCV co-infection, No. (%) 14 (28.0) 45 (43.3) NS
Data are reported as means (standard deviation), or numbers (percentages), as
appropriate.
FR = full responders; INR = immunological non responders; IVDU =
intravenous drug users; MSM = men that make sex with men; HETERO =
heterosexual; CDC = Center for Disease Control and Prevention; HBV =
Hepatitis B; HCV = Hepatitis C; NS = not significant.
doi:10.1371/journal.pone.0027349.t001
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a variable in the final model was set at 0.10. Analyses were
performed using SAS software (version 9.1; SAS Institute, Inc.,
Cary, NC, USA).
Results
Patient characteristics
The clinical and demographic characteristics of the 154 HIV-1-
infected patients are illustrated in Table 1. Fifty (32.5%) patients
were listed as INR, and 104 (67.5%) were considered as FR. The
two groups were similar in clinical-epidemiological and HIV-
related characteristics, except for nadir CD4
+ T-cell count, which
was significantly lower in INR than FR (mean 6 standard
deviation: 62656 versus 1696114 cells/mm
3 respectively,
P,0.0001). Noteworthy, no statistically significant differences
were observed in other variables sometimes associated with
reduced immunological response, such as hepatitis C coinfection,
age, and years of HIV infection, while the long exposure to cART
was lower for INR.
HLA and KIR distribution in the cohort study
The frequencies of the different KIR genes were analyzed in
HIV-infected individuals according to the two possible immuno-
logical outcomes (Table 2): results indicated that the frequency of
inhibitory KIR2DL3 allele was significantly higher in FR than INR
(83.7% vs. 62.0%, P=0.005). Frequency of KIR2DS2 (an
activating KIR which has been found in strong linkage
disequilibrium with KIR2DL2) was found to be statistically higher
in INR than in FR (74.0% versus 54.8%, P=0.03). No statistically
significant differences in frequency of KIR haplotypes (AA and Bx)
were detected between INR and FR. Notably, KIR genotype
frequencies were comparable between HIV-infected subjects and
HC (Table 2).
The distribution of different HLA-B and HLA-C alleles and
ligands showed that HLA-Cw*04:01 was less frequent in INR than
FR (9% vs. 18.8% respectively, P=0.04), while all the other alleles
and ligands distributed without significant differences among the
two groups (Table 3).
We subsequently analyzed the different interactions of all KIR
genes with their HLA-B and HLA-C ligands (Table 4). The co-
presence of KIR and its respective KIR-ligand in the same
individual genotype is referred to as ‘‘functional compound
genotype’’. Interestingly, the functional compound genotype
HLA-C1
+/KIR2DL3
+ is more frequent in full responders: 65.4%
vs. 54%, P=0.02. In contrast, the functional compound genotype
HLA-C1
+/KIR2DL2
+ was found to be more frequent in immuno-
logical non responders, although the difference was not statistically
significant (52% vs. 44.2%, P=0.88). Considering the possibility of
multi-allelic expression, we analyzed the distribution of different
combinations of functional compound genotype between INR and
FR: we found a lower frequency of HLA-C1
+/KIR2DS2
-/
KIR2DL3
+ in INR with respect to FR: 10% vs. 34.6%, OR
0.15, 95%CI 0.04-0.57, P=0.003.
Table 2. KIR alleles and haplotype frequencies distribution in full responders (FR), immunological non responders (INR), and in
healthy controls as reference (HC). Analysis is adjusted for nadir CD4
+ T-cell counts.
KIR gene INR FR crude adjusted HC
no. (%) (N=50) no. (%) (N=104) OR (95% CI) P OR (95% CI) P no. (%) (N=103)
KIR2DL1 47 (94.0) 100 (96.2) 0.63 (0.11–3.70) 0.60 101 (98.1)
KIR2DL2 28 (56.0) 57 (54.8) 1.05 (0.50–2.19) 0.97 60 (58.3)
KIR2DL3 31 (62.0) 87 (83.7) 0.32 (0.14–0.74) 0.005 0.30 (0.12–0.74) 0.009 91 (88.3)
KIR2DL4 47 (94.0) 104 (100) ND 0.03 ND 0.98 101 (98.1)
KIR2DL5A 24 (48.0) 37 (35.6) 1.57 (0.80–3.51) 0.19 41 (39.8)
KIR2DL5B 20 (40.0) 44 (42.3) 0.91 (0.43–1.91) 0.92 30 (29.1)
KIR2DS1 26 (52.0) 37 (35.6) 1.96 (0.94–4.12) 0.07 48 (46.6)
KIR2DS2 37 (74.0) 57 (54.8) 2.35 (1.06–5.27) 0.03 1.93 (0.84–4.46) 0.12 59 (57.3)
KIR2DS3 14 (28.0) 38 (36.5) 0.68 (0.30–1.49) 0.38 42 (40.8)
KIR2DS4*001/002 12 (24.0) 41 (39.4) 0.49 (0.21–1.10) 0.08 16 (15.5)
KIR2DS4*003-006 37 (74.0) 70 (67.3) 1.38 (0.61–3.15) 0.51 52 (50.5)
KIR2DS5 21 (42.0) 31 (29.8) 1.71 (0.80–3.65) 0.18 32 (31.1)
KIR3DL1 46 (92.0) 97 (93.3) ND 0.75 97 (94.2)
KIR3DL2 49 (98.0) 104 (100) ND 0.32 103 (100)
KIR3DL3 50 (100) 104 (100) ND ND 103 (100)
KIR3DS1 21 (42.0) 34 (32.7) 1.49 (0.70–3.17) 0.34 43 (41.7)
KIR2DP1 48 (96.0) 100 (96.2) ND 1.0 102 (99.0)
KIR3DP1*001/002/004 4 (8.0) 20 (19.6) 0.36 (0.12–1.11) 0.11 14 (13.6)
KIR3DP1*003 43 (86.0) 94 (90.4) 0.65 (0.21–2.06) 0.59 100 (97.1)
Haplotype
AA 8 (18.2) 35 (34.0) 0.43 (0.16–1.10) 0.08 25 (24.3)
Bx 36 (81.8) 68 (66.0) 2.32 (0.91–6.07) 0.08 78 (75.7)
NOTE. Data are no. (%) of participants unless otherwise specified. Statistical significance is indicated by a P value of ,0.05. OR, Odds ratio; CI, Confidence Intervals.
doi:10.1371/journal.pone.0027349.t002
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On the basis of univariate analysis, a logistic regression model
was performed considering immunological outcome (INR versus
FR) as dependent variable, and the presence of specific KIR alleles
or KIR-HLA compound genotypes as covariates. The analysis was
adjusted for baseline patient characteristics and is reported in
Tables 2 and 4.
Results indicated that the KIR2DL3 allele is independently
associated with a reduced risk of immunological non responder
status, also after adjusting for nadir CD4
+ T-cell count: OR
(95%CI) 0.30 (0.1220.74), P=0.009. The association seemed also
maintained in the functional compound genotype HLA-C1
+/
KIR2DL3
+: OR (95%CI) 0.34 (0.1320.88), P=0.03.
A low nadir CD4
+ T-cell count is an intrinsic characteristic of
INR; beyond adjusting for it in the multivariable analysis, we also
performed a supplementary analysis by comparing INR and FR
with similar nadir CD4
+ counts (mean 6 standard deviation:
62656 cells/mm
3 in 50 INR versus 79.8676.1 cells/mm
3 in 34
FR, respectively, P.0.05): by excluding all the FR with a high
nadir CD4
+ counts, we still detected a lower frequency of
KIR2DL3 in INR as compared to FR (62% versus 85.3%
respectively, P,0.05).
Discussion
In this study, we investigated for the first time the association
between KIR polymorphism and the magnitude of CD4
+ recovery
in treated HIV-infected individuals with full virologic control.
Interestingly, we found that the presence of KIR2DL3 allele has a
Table 3. Distribution of HLA B and C allele frequencies
between immunological non responders (INR) and full
responders (FR).
HLA INR FR P
no. % h no. % h
B*07:02 6 6.0 12 5.8 0.86
B*08:01 5 5.0 12 5.8 0.99
B*13:01 2 2.0 6 2.9 1
B*13:02 0 0.0 2 1.0 1
B*14:01 0 0.0 1 0.5 1
B*14:02 3 3.0 6 2.9 1
B*15:01 5 5.0 3 1.4 0.1
B*15:09 0 0.0 1 0.5 1
B*15:10 0 0.0 1 0.5 1
B*15:17 2 2.0 2 1.0 1 0.59
B*15:18 0 0.0 1 0.5 1
B*15:24 0 0.0 1 0.5 1
B*18:01 11 11.0 20 9.6 1 0.86
B*18:07 0 0.0 1 0.5 1
B*27:01 2 2.0 5 2.4 1
B*35:01 14 14.0 1 32 15.4 5 0.88
B*35:02 2 2.0 1 0.5 0.25
B*37:01 3 3.0 2 1.0 0.33
B*38:01 8 8.0 11 5.3 0.50
B*39:01 1 1.0 7 3.4 0.44
B*40:01 1 1.0 3 1.4 1
B*40:02 1 1.0 1 0.5 0.55
B*40:08 1 1.0 0 0.0 0.33
B*41:01 2 2.0 0 0.0 0.10
B*44:01 0 0.0 1 0.5 1
B*44:02 3 3.0 13 6.3 0.35
B*44:03 3 3.0 4 1.9 0.68
B*45:01 1 1.0 1 0.5 0.55
B*48:01 1 1.0 1 0.5 0.55
B*49:01 3 3.0 12 5.8 0.40
B*50:01 2 2.0 5 2.4 1
B*51:01 8 8.0 16 7.7 0.89
B*51:04 0 0.0 2 1.0 1
B*52:01 1 1.0 3 1.4 1
B*53:01 1 1.0 2 1.0 1
B*55:01 2 2.0 2 1.0 0.59
B*56:01 0 0.0 1 0.5 1
B*57:01 6 6.0 5 2.4 0.18
B*58:01 0 0.0 7 3.4 0.10
Cw*01:02 3 3.0 5 2.4 0.71
Cw*02:01 0 0.0 2 1 1
Cw*02:02 3 3.0 7 3.4 1
Cw*03:02 4 4.0 2 1.0 0.09
Cw*03:03 5 5.0 5 2.4 0.30
Cw*03:04 3 3.0 3 1.4 0.39
Cw*04:01 9 9.0 39 18.8 5 0.04
Cw*05:01 4 4.0 13 6.3 0.59
HLA INR FR P
no. % h no. % h
Cw*06:02 12 12.0 1 22 10.6 2 0.86
Cw*07:01 16 16.0 1 33 15.9 3 0.89
Cw*07:02 5 5.0 16 7.7 4 0.52
Cw*07:03 1 1.0 1 0.5 0.55
Cw*07:04 3 3.0 1 6 2.9 2 1
Cw*08:01 4 4.0 9 4.3 1
Cw*12:02 11 11.0 2 10 4.8 1 0.08
Cw*12:03 6 6.0 14 6.7 0.99
Cw*12:04 0 0.0 1 0.5 1
Cw*14:01 0 0.0 1 0.5 1
Cw*14:02 1 1.0 4 1.9 1
Cw*15:02 5 5.0 3 1.4 0.12
Cw*16:01 2 2.0 11 5.3 1 0.23
Cw*16:02 1 1.0 1 0.5 0.55
Cw*17:01 2 2.0 0 0.0 0.10
C1 63 63.0 121 58.2 0.49
C2 37 37.0 87 41.8
Bw4 43 43.0 93 44.7 0.87
Bw6 57 57.0 115 55.3
NOTE. Data are expressed as number (no.) of alleles and percentages (%)
calculated on the total number of alleles per group (INR=100 alleles; FR=208
alleles). For each allele, the number of homozygous (h) subjects were reported.
Statistical significance is indicated by a P value of ,0.05.
doi:10.1371/journal.pone.0027349.t003
Table 3. Cont.
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+ T-cell counts.
KIR/KIR-ligands INR FR crude adjusted
no % no % P OR (95%CI) P OR (95%CI)
2DS1
+/C2
+ 18 36.0 20 19.2 0.02 3.02 (1.16–7.96) 0.04 2.84 (1.04–7.76)
2DS1
2/C2
+ 14 28.0 47 45.2
2DS1
+/C2
2 8 16.0 17 16.3 0.85 0.94 (0.26–3.37)
2DS1
2/C2
2 10 20.0 20 19.2
2DL1
+/C2
+ 30 60.0 66 63.5 0.24 0.23 (0.01–3.39)
2DL1
2/C2
+ 2 4.0 1 1.0
2DL1
+/C2
2 17 34.0 34 32.7 1.0 ND
2DL1
2/C2
2 1 2.0 3 2.9
2DL2
+/C1
+ 26 52.0 46 44.2 0.88 1.13 (0.51–2.51)
2DL2
2/C1
+ 19 38.0 38 36.5
2DL2
+/C1
2 2 4.0 11 10.6 0.64 ND
2DL2
2/C1
2 3 6.0 9 8.7
2DL3
+/C1
+ 27 54.0 68 65.4 0.02 0.35 (0.15–0.85) 0.03 0.34 (0.13–0.88)
2DL3
2/C1
+ 18 36.0 16 15.4
2DL3
+/C1
2 4 8.0 19 18.3 0.36 ND
2DL3
2/C1
2 1 2.0 1 1.0
2DS2
+/C1
+ 35 70.0 46 44.2 0.02 2.89 (1.19–7.18) 0.06 2.41 (0.95–6.12)
2DS2
2/C1
+ 10 20.0 38 36.5
2DS2
+/C1
2 2 4.0 11 10.6 0.64 ND
2DS2
2/C1
2 3 6.0 9 8.6
2DS4*001
+/Cw*04
+ 0 0.0 13 12.5 0.04 ND
2DS4*001
2/Cw*04
+ 9 18.0 21 20.2
2DS4*001
+/Cw*04
2 12 24.0 28 26.9 0.39 1.56 (0.63–3.88)
2DS4*001
2/Cw*04
2 29 58.0 42 40.4
2DS4*003
+/Cw*04
+ 8 16.0 21 20.2 0.83 ND
2DS4*003
2/Cw*04
+ 1 2.0 13 12.5
2DS4*003
+/Cw*04
2 29 58.0 49 47.1 0.89 1.04 (0.41–2.63)
2DS4*003
2/Cw*04
2 12 24.0 21 20.2
3DL1
+/Bw4
+ 30 60.0 63 60.6 0.68 0.63 (0.11–3.86)
3DL1
2/Bw4
+ 3 6.0 4 3.8
3DL1
+/Bw4
2 16 32.0 33 31.7 1.00 ND
3DL1
2/Bw4
2 1 2.0 3 2.9
3DS1
+/Bw4
+ 13 26.0 19 18.3 0.37 1.64 (0.62–4.32)
3DS1
2/Bw4
+ 20 40.0 48 46.2
3DS1
+/Bw4
2 8 16.0 15 14.4 0.94 1.24 (0.33–4.63)
3DS1
2/Bw4
2 9 18.0 21 20.2
C1
+/2DL2
+/2DL3
+ 13 26.0 32 30.8 0.04 0.16 (0.02–1.14) 0.06 0.15 (0.02–1.13)
C1
+/2DL2
2/2DL3
2 5 10.0 2 1.9
C1
+/2DL2
2/2DL3
+ 14 28.0 36 34.6 0.13 0.42 (0.14–1.24)
C1
+/2DL2
+/2DL3
2 13 26.0 14 13.5
C1
+/2DS2
+/2DL3
+ 22 44.0 32 30.8 0.22 0.28 (0.03–1.83)
C1
+/2DS2
2/2DL3
2 5 10.0 2 1.9
C1
+/2DS2
2/2DL3
+ 5 10.0 36 34.6 0.003 0.15 (0.04–0.57) 0.01 0.16 (0.04–0.64)
C1
+/2DS2
+/2DL3
2 13 26.0 14 13.5
NOTE. Data are numbers (no.) and percentages (%) of participants unless otherwise specified. Statistical significance is indicated by a P value of ,0.05.
The presence of KIR-ligand genotype is considered
+ when observed in at least one allele: C1
2 =C 1
2/2;C 1
+ =C 1
+/+ or C1
+/2;C 2
2 =C 2
2/2;C 2
+ =C 2
+/+ or C2
+/2;
Cw*04
2 = Cw*04
2/2; Cw*04
+ = Cw*04
+/+ or Cw*04
+/2; Bw4
2 = Bw4
2/2;B w 4
+ = Bw4
+/+ or Bw4
+/2.
OR, Odds ratio; CI, Confidence Intervals; ND, not determined.
doi:10.1371/journal.pone.0027349.t004
KIR Genotypes in Immunological Non Responders
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27349strong ‘‘protective effect’’ against becoming an immunological non
responder.
The mechanisms which hinder full immune restoration in HIV-
infected cART-treated patients remain unclear. Previous studies
focused on impaired homeostasis of T-cell adaptive immunity,
leading to a more rapid T-cell turnover and apoptosis in
immunological non responders [17]. The trigger for this process is
still poorly defined, and possibly involves the HIV proviral burden.
The influence that genetic factors have in natural control of HIV
disease in untreated individuals suggests a possible role of innate
immunity in determining the magnitude of immunological recovery
after successful cART. In our work, we tested this hypothesis by
comparing the frequencies of different KIR and HLA polymor-
phisms in immunological non responders and full responders.
Despite the small numbers, the two groups are quite
homogeneous for demographic and HIV-related characteristics.
The only strong significant difference was, predictably, in nadir
CD4
+ T-cell count. It is well known, in fact, that low CD4
+ nadir
is predictive of incomplete immune recovery [18,19]. The two
groups differ also for the duration of antiretroviral therapy, but, at
the same time, all the patients have been treated for a mean of
more than ten years; therefore, the possibility that a small
difference in long cART duration could influence the magnitude
of immune recovery seems negligible.
By comparing the frequencies of all the identified KIR and
HLA alleles, we observed that KIR2DL3 was associated with a
reduced risk of becoming an immunological non responder to
cART; notably, this strong and significant association was
maintained after adjusting for nadir CD4
+ T-cell count.
KIR2DL3 and KIR2DL2 are different alleles at the same locus:
both are inhibitory KIRs, but KIR2DL3 has a weaker inhibitory
potential [20]. KIR2DL3’s weaker inhibition may result in greater
activation of NK cells and, consequently, in more efficient control
of viral infection. The potency of KIR2DL3 varies according to
the HLA-C subtypes expressed. In our work, the ‘‘protective
effect’’ of KIR2DL3 against becoming an immunological non
responders is evident also when we considered the combined
KIR/KIR-ligand genotype, in this case HLA-C1. Also, an
additional explanation for consideration is that the virus could
have accumulated escape variants in certain HLA-C restricted
epitopes (drug or T-cell driven), leading to a loss of HLA-C
binding to KIR2DL3. This could also lead to increased NK cell
killing. We do not have information on viral sequences, but this
might prove an interesting follow-up analyses.
Similar results have been found in another model of treatment of a
persistentviralinfection,hepatitisC(HCV):thepresenceofKIR2DL3
was associated with better response to anti-HCV treatment [21].
Our findings support a role of the KIR2DL3 allele in producing
sustained immune recovery, although the corresponding mecha-
nisms could be only postulated. Recently, it has been suggested
that NK cell loss during SIV infection in pigtail macaques could
favour gut damage and microbial translocation, thus resulting in
rapid disease progression [22]. Microbial translocation seems also
to influence the magnitude of immunological recovery in treated
individuals [23]. Therefore we could speculate that weaker NK
activity at mucosal level (a result of the balance of inhibitory and
activating KIRs) is associated with increased gut damage, and
subsequent microbial translocation and immune activation.
Higher levels of immune activation have been described in
immunological non responders [4], and are associated with
impaired T-cell homeostasis [23]. Additional functional studies
will be necessary to clarify this hypothesis.
Another mechanism possibly hindering full immune recovery
might involve NK cells in their role of killing latently HIV-infected
cells. NK cells kill ‘missing self’ targets as a result of the balance
between inhibitory and activating signals transmitted by different
KIR molecules [24]. Thus, it is possible to speculate that reduced
killing capacity (due to decreased presenceof KIR2DL3) is associated
with a higher proviral DNA burden in peripheral blood mononuclear
cells, which in turn has been associated with incomplete immune
restoration in immunological non responders [17].
Finally, we could hypothesize that the preservation of
competent NK cells, through a favorable equilibrium between
activating and inhibitory KIRs, might promote CD4
+ T-cell
recovery (via dendritic cells or directly through cytokine
production).
Our study has some important limitations: due to the
exploratory nature of the analysis, we did not apply any
adjustment for multiple comparisons. However, our initial findings
on the different distribution of KIR2DL3 between INR and FR
prompt to test this hypothesis on a larger cohort.
Another drawback of the study is that the two groups differ for
nadir CD4
+ T-cell counts, which is strongly associated with INR
status. All the other characteristics were fairly similar in the two
groups: of note, time of exposure to cART was quite long and not
so different between INR and FR, thus suggesting that INRs were
‘true’ immunological non responders and FR were ‘true’ full
responders, irrespective of their baseline CD4
+ T-cell counts. In
order to ascertain the possible role of nadir CD4
+ T-cell counts as
a confounder, we adjusted our analysis in a multivariate model,
and we still found that KIR2DL3 allele is reduced in INR as
compared to FR. Moreover, when we consider only patients with
low nadir CD4
+ T-cell counts in the two groups, we found no
difference in nadir CD4
+ counts, and the frequency of KIR2DL3
allele remains significantly lower in INR than in FR.
Our study, although hypothesis-generating, lacks functional
assays to verify the proposed mechanisms. However, these
preliminary findings are the first to suggest a possible link between
KIR polymorphism and the magnitude of immunological response
to cART in HIV infection, opening the way to new research
directions in this field.
In conclusion, the reduced presence of the inhibitory KIR2DL3
genotype in INR could be associated with a higher frequency of
other KIR genotypes with stronger inhibitory potential, such as
KIR2DL2. The observed reduction of inhibitory KIR likely results
in increased immune activation; impaired killing of latently
infected cells; and a higher proviral burden. These factors can
justify incomplete immune recovery during therapy. The presence
of different combinations of KIR inhibitory and activating genes –
and their interaction with HLA – thereby warrants further
evaluation, since it could prove useful as a predictor of
immunological response to fully virologically effective cART.
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